Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
EDQM
0
USP
0
JP
0
Others
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
API
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. 3-(2,4-bis((3s)-3-methylmorpholin-4-yl)pyrido(5,6-e)pyrimidin-7-yl)-n-methylbenzamide
2. Azd-2014
3. Azd2014
1. Azd2014
2. 1009298-59-2
3. Azd-2014
4. Vistusertib [inn]
5. Azd 2014
6. 3-[2,4-bis((3s)-3-methylmorpholin-4-yl)pyrido[5,6-e]pyrimidin-7-yl]-n-methylbenzamide
7. Vistusertib (azd-2014)
8. Vistusertib [usan]
9. Vistusertib (azd2014)
10. 0bsc3p4h5x
11. Chembl2336325
12. 3-(2,4-bis((s)-3-methylmorpholino)pyrido[2,3-d]pyrimidin-7-yl)-n-methylbenzamide
13. 3-[2,4-bis[(3s)-3-methylmorpholin-4-yl]pyrido[2,3-d]pyrimidin-7-yl]-n-methylbenzamide
14. Benzamide, 3-(2,4-bis((3s)-3-methyl-4-morpholinyl)pyrido(2,3-d)pyrimidin-7-yl)-n-methyl-
15. 3-(2,4-bis((3s)-3-methylmorpholin-4-yl)pyrido(5,6-e)pyrimidin-7-yl)-n-methylbenzamide
16. Unii-0bsc3p4h5x
17. Cc-551
18. Benzamide, 3-[2,4-bis[(3s)-3-methyl-4-morpholinyl]pyrido[2,3-d]pyrimidin-7-yl]-n-methyl-
19. 3-[2,4-bis((3s)-3-methylmorpholin-4-yl)pyrido-[5,6-e]pyrimidin-7-yl]-n-methylbenzamide
20. Vistusertib (jan/inn)
21. Vistusertib [jan]
22. Vistusertib [usan:inn]
23. Vistusertib [who-dd]
24. Mls006011011
25. Schembl290672
26. Gtpl7699
27. Dtxsid20143584
28. Ex-a155
29. Amy24188
30. Bcp05748
31. Bdbm50429701
32. Mfcd22628784
33. Nsc767189
34. Nsc780879
35. Nsc787289
36. Nsc799345
37. S2783
38. Zinc59258964
39. Akos024464879
40. Bcp9000362
41. Ccg-269370
42. Cs-0701
43. Db11925
44. Nsc-767189
45. Nsc-780879
46. Nsc-787289
47. Nsc-799345
48. Ncgc00346698-04
49. Ncgc00346698-11
50. Ncgc00346698-12
51. Ac-28425
52. As-16302
53. Hy-15247
54. Smr004702809
55. Sw219704-1
56. D10887
57. J-000268
58. Q27089147
59. 3-[2,4-bis-[(3s)-3-methyl-4-morpholinyl]-pyrido[2,3-d]pyrimidin-7-yl]-n-methylbenzamide
60. 3-(2,4-bis((3s)-3-methyl-4-morpholinyl)pyrido(2,3-d)pyrimidin-7-yl)-n-methylbenzamide
| Molecular Weight | 462.5 g/mol |
|---|---|
| Molecular Formula | C25H30N6O3 |
| XLogP3 | 2.8 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 8 |
| Rotatable Bond Count | 4 |
| Exact Mass | 462.23793884 g/mol |
| Monoisotopic Mass | 462.23793884 g/mol |
| Topological Polar Surface Area | 92.7 Ų |
| Heavy Atom Count | 34 |
| Formal Charge | 0 |
| Complexity | 698 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 2 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Digital Content 
NEWS #PharmaBuzz
ABOUT THIS PAGE
87
PharmaCompass offers a list of Vistusertib API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Vistusertib manufacturer or Vistusertib supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Vistusertib manufacturer or Vistusertib supplier.
PharmaCompass also assists you with knowing the Vistusertib API Price utilized in the formulation of products. Vistusertib API Price is not always fixed or binding as the Vistusertib Price is obtained through a variety of data sources. The Vistusertib Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Vistusertib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Vistusertib, including repackagers and relabelers. The FDA regulates Vistusertib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Vistusertib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Vistusertib supplier is an individual or a company that provides Vistusertib active pharmaceutical ingredient (API) or Vistusertib finished formulations upon request. The Vistusertib suppliers may include Vistusertib API manufacturers, exporters, distributors and traders.
Vistusertib Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Vistusertib GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Vistusertib GMP manufacturer or Vistusertib GMP API supplier for your needs.
A Vistusertib CoA (Certificate of Analysis) is a formal document that attests to Vistusertib's compliance with Vistusertib specifications and serves as a tool for batch-level quality control.
Vistusertib CoA mostly includes findings from lab analyses of a specific batch. For each Vistusertib CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Vistusertib may be tested according to a variety of international standards, such as European Pharmacopoeia (Vistusertib EP), Vistusertib JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Vistusertib USP).
